The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
128
0.5ml administered onto the sclera once every six months for 24 months
0.5ml administered onto the sclera once every six months for 24 months
0.5ml administered onto the sclera once every six months for 24 months
Mean change in logMAR visual acuity at 12 months from baseline.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0.5ml administered onto the sclera once every six months for 24 months